[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy].
A 65-year-old female who underwent radical mastectomy on 28 April 1988 felt swelling and numbness of her left lower jaw. As a result of bone biopsy and scintigraphy, multiple bone metastasis was diagnosed. After 6 cycles of CMF therapy, the swelling and numbness of the left lower jaw were reduced, but atelectasis of the left lung upper lobe appeared. After 10 cycles of paclitaxel therapy, atelectasis and bone metastasis were reduced. Daily oral chemoendocrine combination therapy, DMpC therapy (5'-DFUR 800 mg/day + CPA 100 mg/day + MPA 800 mg/day) was continued for 12 months. No recurrent signs and serious side effects were observed during DMpC therapy.
Miyamoto
Hidenori
H
Dept. of Surgery, OE Kyohdoh Hospital.
Yoshida
Sadahiro
S
Imatomi
Michiaki
M
Saitoh
Tsuneo
T
Nakata
Akiyasu
A
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D005467:Floxuridine; D003520:Cyclophosphamide; D017258:Medroxyprogesterone Acetate; C025034:doxifluridine